EUDA Health Holdings Limited announced on September 4, 2025, that it has secured distribution rights for T-cell immunotherapies in Malaysia. These therapies are developed by Shenzhen Inno Immune Co. Ltd. ('Shenzhen Inno'), a Chinese developer of autologous cellular therapeutic and customized medicines.
This strategic move expands EUDA's advanced biotechnology portfolio, complementing its existing stem cell therapy initiatives. The expansion into T-cell immunotherapy reinforces the company's integrated approach to regenerative health and longevity.
The addition of T-cell immunotherapies is critical to EUDA's mission to transform the health and wellness landscape in Asia. It offers long-term growth potential amid rising demand for science-backed immunity and longevity solutions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.